Bright Minds Biosciences Inc. (DRUG) has been able to initiate its phase 2 BREAKTHROUGH study using its 5-HT2C agonist BMB-101 for the treatment of adult patients with classic Absence Epilepsy and ...

Detailed price information for Bright Minds Biosciences Inc (DRUG-Q) from The Globe and Mail including charting and trades.

Absence: 73.1% median reduction in the number of absence seizure ≥3s, p = 0.012 DEE: 63.3% median reduction in major motor seizures REM sleep improvement in patients with Absence Seizures: mean 90% ...

A randomized, double-blind clinical trial that compared three widely used anticonvulsants for childhood absence epilepsy established that ethosuximide was the most appropriate first-line therapy for ...

Bright Minds Biosciences has debuted glowing phase 2 results for its lead anti-seizure asset, giving the biotech’s stock a jolt and setting up future registrational trials for the serotonin receptor ...

“Do you know why you shouldn’t talk to strangers?” asks a police officer standing at the front of a classroom to a room full of students. Emily’s hand shoots up and the teacher encourages her to ...

Researchers aimed to identify the characteristics, treatment pathways, and outcomes associated with epilepsy with eyelid myoclonia (EEM). Epilepsy with eyelid myoclonia (EEM) is a rare and ...

Epilepsy is not a one size fits all condition and there are a few tell tale signs that parents could miss, said Dr Jonathan Redelinghuys.

“Do you know why you shouldn’t talk to strangers?” asks a police officer standing at the front of a classroom to a room full of students. Emily’s hand shoots up and the teacher encourages her to ...